Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial.
Zimmermann H, Koenecke C, Dreyling MH, Pott C, Dührsen U, Hahn D, Meidenbauer N, Hauser IA, Rummel MJ, Wolf D, Heuser M, Schmidt C, Schlattmann P, Ritgen M, Siebert R, Oschlies I, Anagnostopoulos I, Trappe RU. Zimmermann H, et al. Among authors: anagnostopoulos i. Leukemia. 2022 Oct;36(10):2468-2478. doi: 10.1038/s41375-022-01667-1. Epub 2022 Aug 16. Leukemia. 2022. PMID: 35974101 Free PMC article. Clinical Trial.
Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
Trappe RU, Choquet S, Reinke P, Dreyling M, Mergenthaler HG, Jäger U, Kebelmann-Betzing C, Jonas S, Lehmkuhl H, Anagnostopoulos I, Leblond V, Hetzer R, Dörken B, Riess H, Oertel S. Trappe RU, et al. Among authors: anagnostopoulos i. Transplantation. 2007 Dec 27;84(12):1708-12. doi: 10.1097/01.tp.0000295987.12996.19. Transplantation. 2007. PMID: 18165786
Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone.
Trappe R, Riess H, Anagnostopoulos I, Neuhaus R, Gärtner BC, Pohl H, Müller HP, Jonas S, Papp-Vary M, Oertel S. Trappe R, et al. Among authors: anagnostopoulos i. Ann Hematol. 2009 Feb;88(2):167-72. doi: 10.1007/s00277-008-0538-0. Epub 2008 Jul 18. Ann Hematol. 2009. PMID: 18636261 No abstract available.
Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression.
Trappe R, Hinrichs C, Appel U, Babel N, Reinke P, Neumayer HH, Budde K, Dreyling M, Dührsen U, Kliem V, Schüttrumpf S, Hauser IA, Mergenthaler HG, Schlattmann P, Anagnostopoulos I, Doerken B, Riess H. Trappe R, et al. Among authors: anagnostopoulos i. Am J Transplant. 2009 Oct;9(10):2331-7. doi: 10.1111/j.1600-6143.2009.02772.x. Epub 2009 Aug 6. Am J Transplant. 2009. PMID: 19663889 Free article.
IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment.
Hinrichs C, Wendland S, Zimmermann H, Eurich D, Neuhaus R, Schlattmann P, Babel N, Riess H, Gärtner B, Anagnostopoulos I, Reinke P, Trappe RU. Hinrichs C, et al. Among authors: anagnostopoulos i. Transpl Int. 2011 Sep;24(9):892-903. doi: 10.1111/j.1432-2277.2011.01282.x. Epub 2011 Jun 11. Transpl Int. 2011. PMID: 21668529 Free article. Clinical Trial.
Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases.
Trappe R, Zimmermann H, Fink S, Reinke P, Dreyling M, Pascher A, Lehmkuhl H, Gärtner B, Anagnostopoulos I, Riess H. Trappe R, et al. Among authors: anagnostopoulos i. Haematologica. 2011 Jul;96(7):1067-71. doi: 10.3324/haematol.2010.039214. Haematologica. 2011. PMID: 21719885 Free PMC article.
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S; German PTLD Study Group; European PTLD Network. Trappe R, et al. Among authors: anagnostopoulos i. Lancet Oncol. 2012 Feb;13(2):196-206. doi: 10.1016/S1470-2045(11)70300-X. Epub 2011 Dec 13. Lancet Oncol. 2012. PMID: 22173060 Clinical Trial.
Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry.
Zimmermann H, Oschlies I, Fink S, Pott C, Neumayer HH, Lehmkuhl H, Hauser IA, Dreyling M, Kneba M, Gärtner B, Anagnostopoulos I, Riess H, Klapper W, Trappe RU. Zimmermann H, et al. Among authors: anagnostopoulos i. Transplantation. 2012 Mar 15;93(5):543-50. doi: 10.1097/TP.0b013e318242162d. Transplantation. 2012. PMID: 22234349
270 results